{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage&page=8", "query": { "condition": "Ovarian Cancer Stage", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1634, "total_pages": 164, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T02:14:25.921Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003425", "title": "Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Leukemia", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Kentucky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "14 Years to 70 Years" }, "enrollment_count": 25, "start_date": "1997-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-26", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 4, "location_summary": "Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003425" }, { "nct_id": "NCT06457997", "title": "A Study of PHN-010 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Colon Cancer", "Endometrial Cancer", "Ovarian Cancer", "Cervical Cancer", "Advanced Solid Tumor", "Advanced Cancer" ], "interventions": [ { "name": "PHN-010", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pheon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2024-07-01", "completion_date": "2025-09-11", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 8, "location_summary": "Orlando, Florida • Boston, Massachusetts • New York, New York + 5 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06457997" }, { "nct_id": "NCT02262455", "title": "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "Solid Tumors" ], "interventions": [ { "name": "STM 434", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santa Maria Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2014-10", "completion_date": "2017-01-13", "has_results": false, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02262455" }, { "nct_id": "NCT03394885", "title": "Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2018-06-19", "completion_date": "2020-07-20", "has_results": true, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Durham, North Carolina • Charlottesville, Virginia", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03394885" }, { "nct_id": "NCT07433660", "title": "WellSpan-THRIVE Cancer QOL Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative", "Cancer (Solid Tumors)", "Cancer (With or Without Metastasis)", "Cancer - Ovarian", "Cancer Abdomen", "Cancer (Advanced Stage)" ], "interventions": [], "intervention_types": [], "sponsor": "WellSpan Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2026-02", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 5, "location_summary": "Chambersburg, Pennsylvania • Ephrata, Pennsylvania • Gettysburg, Pennsylvania + 2 more", "locations": [ { "city": "Chambersburg", "state": "Pennsylvania" }, { "city": "Ephrata", "state": "Pennsylvania" }, { "city": "Gettysburg", "state": "Pennsylvania" }, { "city": "Lebanon", "state": "Pennsylvania" }, { "city": "York", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07433660" }, { "nct_id": "NCT01033123", "title": "A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "BSI-201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 41, "start_date": "2009-12", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01033123" }, { "nct_id": "NCT05317078", "title": "A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-squamous Non-small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "AMG 794", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-02-28", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05317078" }, { "nct_id": "NCT00061308", "title": "Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peritoneal Cancer", "Ovarian Cancer", "Neoplasms, Ovarian", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 75, "start_date": "2002-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-06-09", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 15, "location_summary": "Los Gatos, California • Santa Rosa, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Los Gatos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061308" }, { "nct_id": "NCT04768868", "title": "The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "IMP7068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Impact Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2021-02-25", "completion_date": "2023-08-30", "has_results": false, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Fairway, Kansas • Louisville, Kentucky + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04768868" }, { "nct_id": "NCT06714617", "title": "Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Stage III", "HER2-positive Metastatic Breast Cancer", "Unresectable Breast Carcinoma", "Her2-Positive", "HER2 Gene Mutation", "Gastroesophageal-junction Cancer", "Non Small Cell Lung Cancer", "Endometrial Neoplasms", "Peritoneal Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Urothelial Carcinoma Bladder", "Solid Tumor, Adult", "Gastric Cancer" ], "interventions": [ { "name": "BL-M17D1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2025-04-10", "completion_date": "2026-01-30", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-21T02:14:25.921Z", "location_count": 9, "location_summary": "Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06714617" } ] }